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Edited by Veli-Pekka LehtoAbstract Erythropoietin (Epo) mRNA expression is suppressed
by interleukin 1 (IL-1). Cyclic adenosine monophosphate
(cAMP) can increase Epo mRNA and Epo protein levels in
IL-1 treated HepG2 cells to some extent. To identify molecular
mechanisms of this reaction we investigated three transcription
factors (NF-jB, GATA-2 and HIF-1) that control the Epo gene.
Western blot analyses and electrophoretic mobility shift assays
(EMSAs) revealed that IL-1 strongly activated NF-jB, which
is a likely suppressor of the Epo promoter. Treatment of the cells
with dibutyryl-cAMP (Bt2-cAMP) inhibited the activation of
NF-jB by IL-1. Bt2-cAMP increased GATA-2 DNA binding.
Since GATA-2 is a suppressor of the Epo promoter, GATA-2
activation was unlikely to cause the increase of Epo mRNA
expression in IL-1 treated cells. Furthermore, Western blots,
EMSAs and reporter gene studies showed that Bt2-cAMP was
without eﬀect on the hypoxia-inducible transcription factor
HIF-1. Thus, NF-jB is probably the primary transcription fac-
tor by which cAMP counteracts the inhibition of Epo gene
expression by IL-1.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The erythropoietin (Epo) gene possesses several regulatory
DNA elements. GATA-2, a zinc ﬁnger transcription factor,
binds to the GATA motif located in the 30 region relative
to the transcriptional initiation site of the Epo promoter,
thereby inhibiting Epo gene expression [1,2]. Furthermore,
the 5 0 region of the Epo gene contains binding sites for NF-
jB [3]. The 50 bp hypoxia-responsive element (HRE) of the
3 0 enhancer contains a hypoxia-inducible factor (HIF) binding
site (HBS), a CACA sequence, and a direct repeat of two ste-
roid hormone receptor-binding half-sites separated by two
base pairs (DR-2 element) [4]. Hypoxia-inducible-factor-1
(HIF-1) is a crucial transcription factor for the hypoxic induc-Abbreviations: ACD, anemia of chronic disease; Bt2-cAMP, dibutyryl-
cyclic adenosine monophosphate; EMSA, electrophoretic mobility
shift assay; Epo, erythropoietin; HIF-1, hypoxia-inducible factor-1;
HRE, hypoxia-response element; IL, interleukin; TNF, tumor necrosis
factor
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doi:10.1016/j.febslet.2006.04.069tion of the Epo gene [5]. Activated HIF-1 is composed of two
subunits, HIF-1a and HIF-1b [6], with HIF-1a being unstable
in the presence of O2 (for Refs. see [7,8]).
We have recently shown that the proinﬂammatory cytokines
interleukin 1 (IL-1) and tumor necrosis factor-a (TNF-a) acti-
vate GATA-2 and NF-jB [9]. IL-1 and TNF-a have proved to
inhibit Epo mRNA expression and Epo synthesis in the human
hepatoma cell lines, Hep3B and HepG2 [10–12] and in rat kid-
neys [11,13]. On the other hand, cyclic adenosine monophos-
phate (cAMP) has been reported to stimulate Epo synthesis
in hepatic and renal cell lines [14,15] and to counteract the
inhibitory action of IL-1 and TNF-a on Epo synthesis [12].
The present study aimed at investigating molecular mecha-
nisms by which cAMP prevents the suppression of Epo mRNA
expression and Epo production by IL-1. Results obtained by
Western blotting, electrophoretic mobility shift assays, repor-
ter gene studies, Epo mRNA quantiﬁcation and Epo immuno-
assay suggested that cAMP restores Epo production in IL-1
treated HepG2 cells by preventing NF-jB mobilization rather
than through modulating GATA-2 or HIF-1 signaling.2. Materials and methods
2.1. Cell cultures
The human hepatoma cell line HepG2 was purchased from the Ger-
man Collection of Microorganisms and Cell Cultures (DSMZ, Braun-
schweig). Cells were grown in RPMI 1640 medium (Gibco, Karlsruhe,
Germany) supplemented with 10% fetal calf serum (FCS; Gibco).
Medium for the HepG2 derivatives HRG1, IjBa-HepG2 and
IjBaM-HepG2 [9,16] was supplemented with 50 lg/ml G418,
100 IU/ml penicillin and 100 lg/ml streptomycin (PAA Laborato-
ries, Co¨lbe, Germany). Recombinant human IL-1b was a gift from
Ciba-Geigy (Basel, Switzerland). Dibutyryl-cAMP (Bt2-cAMP) was
obtained from Sigma (Taufkirchen, Germany). Cell cultures were
maintained at 37 C in a humidiﬁed atmosphere containing 5% CO2
and subcultivated two to three times a week. Cells received fresh med-
ium the day before the experiments. For study of hypoxia, cells were
placed in a humidiﬁed atmosphere containing 3% O2, 5% CO2 and bal-
anced N2 (Heraeus incubators, Hanau, Germany). In order to exclude
cytotoxic eﬀects of IL-1b and Bt2-cAMP, the colorimetric tetrazolium
salt/formazan method was applied, which is based on the reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT;
Sigma) to purple formazan in living cells. Conﬂuent HepG2 cultures
in 96-well dishes were used for these studies as described [17].
2.2. Nuclear protein extraction
Nuclear proteins were extracted as described in detail elsewhere
[9,18]. HepG2 cells were washed with ice-cold phosphate-buﬀered sal-
ine (PBS), scraped oﬀ and collected. For Western blot and electropho-
retic mobility shift assay (EMSA) analysis of NF-jB and GATA-2, the
cell suspensions were centrifuged at 4000 · g and 4 C for 5 min. Pel-
leted cells were resuspended in 350 ll buﬀer containing 10 mMHEPESblished by Elsevier B.V. All rights reserved.
Fig. 1. (A) Epo concentrations in cell culture supernatants of HepG2
cells exposed to 3% O2 without drugs (HOX) or with 50 lMBt2-cAMP
(HOX + cAMP), 300 pg/ml IL-1 (HOX + IL-1) or the combination of
IL-1 and Bt2-cAMP (HOX + IL-1 + cAMP) for 24 h. *P 6 0.05
compared to the respective cultures without Bt2-cAMP, mean + SD,
n = 5, Student’s t-test. (B) Epo mRNA levels quantiﬁed by real-time
RT-PCR of extracts of HepG2 cells exposed to 3% O2 without drugs
(HOX) or with 50 lM Bt2-cAMP (HOX + cAMP), 300 pg/ml IL-1
(HOX + IL-1) or the combination of IL-1 and Bt2-cAMP (HOX + IL-
1 + cAMP) for 8 h. Expression levels normalized to L28 and related to
HOX were calculated with the DDCT method. *P 6 0.05 compared
to the respective cultures without Bt2-cAMP, mean + SD, n = 6,
Student’s t-test.
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15 min. For cell lysis 25 ll of 10% NP-40 solution was added and
mixed vigorously for 30 s. Nuclei were collected by centrifugation
and resuspended in 60 ll buﬀer containing 20 mM HEPES (pH 7.9),
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and 25% glycerol.
The suspension was gently agitated on a shaking platform on ice for
20 min. Nuclei were centrifuged at 12500 · g and 4 C for 5 min and
the extracts stored at 80 C.
For Western blot and EMSA analysis of HIF-1, cell suspensions
were centrifuged at 800 · g and 4 C for 5 min. Cell pellets were
washed with 2 ml buﬀer A (10 mM Tris (pH 7.8), 1.5 mM MgCl2,
10 mM KCl) and subsequently resuspended in 1 ml buﬀer A and
placed on ice for 30 min. Nuclei were collected by centrifugation and
resuspended in 100 ll buﬀer C (10 mM KCl, 20 mM Tris (pH 7.8),
1.5 mMMgCl2, 20% glycerol) by gentle up and down pipetting. Nuclei
were pelleted by centrifugation at 13000 · g and 4 C for 30 min.
Supernatants were stored at 80 C. Immediately before use, buﬀers
A and C were supplemented with 2 lg/ml aprotonin, 10 lg/ml leupep-
tin, 20 lg/ml pepstatin, 1 mM sodium ortho-vanadate, 0.5 mM ben-
zamidine, 2 mM levamisole, 10 mM b-glycerophosphate, 0.5 mM
dithiothreitol (DDT) and 0.4 mM phenylmethylsulfonyl ﬂuoride
(PMSF). Protein concentrations were determined by the Bradford
method [19] with bovine serum albumin (BSA) as standard.
2.3. Western blotting
Samples (25 lg of nuclear extracts) were run on denaturing 10% (for
NF-jB subunits) or denaturing 7.5% (for HIF-1a) polyacrylamide gels
and transferred to nitrocellulose-membranes (Hybond; Amersham,
Biosciences). Transfer eﬃciency was veriﬁed by staining with 2% Pon-
ceau S and/or immunodetection of SP1 or b-actin. Membranes were
blocked overnight at 4 C in 5% skim milk/PBS and then incubated
with the respective antibody at room temperature for 2 h. Antibodies
anti-NF-jB-p50, anti-NF-jB-p65, anti-SP1, anti-b-actin were from
Santa Cruz (Heidelberg, Germany) and anti-HIF-1a was from BD
Biosciences (Heidelberg, Germany). All antibodies were used in a dilu-
tion of 1:1000 in 5% skimmed milk in PBS. For detection, matched
horseradish peroxidase conjugated secondary antibodies in a 1:2000
dilution (all from DAKO, Hamburg, Germany) and enhanced chemi-
luminescence substrate (Amersham, Freiburg, Germany) were used.
2.4. Electrophoretic mobility shift assay
NF-jB and GATA-2 EMSAs were performed as described in [9] and
HIF-1 EMSAs as in [18]. Oligonucleotide sequences were as follows:
NF-jB sense: 5 0-AGT TGA GGG GAC TTT CCC-30; NF-jB anti-
sense: 5 0-GCC TGG GAA AGT CCC CTC-3 0; GATA-2 sense:
5 0-CAC ACA TGC AGA TAA CAG CCC CGA CC-3 0; GATA-2
antisense: 5 0-GGT CGG GGC TGT TAT CTG GAT GTG TG-3 0;
HIF-1 sense: 5 0-TTC CTG CAC GTA CAC ACA AAG CGC ACG
TAT TTC-3 0; HIF-1 antisense: 5 0-GAA ATA CGT GCG CTT TGT
GTG TAC GTG CAG GAA-3 0. Oligonucleotides (MWG, Ebersberg,
Germany) were labeled with T4 polynucleotide kinase (MBI Fermen-
tas, St. Leon-Rot, Germany) in the presence of c-[32P]-ATP (NEN,
Ko¨ln, Germany). Protein–DNA complexes were resolved by electro-
phoresis in non-denaturing 6% polyacrylamide gels. For supershift
analyses, anti-NF-jB-p50, NF-jB-p65 (all from Santa Cruz, Heidel-
berg) and anti-HIF-1a (BD Biosciences) were used.
2.5. Luciferase assays
HRG-1 cells, which are HepG2 cells stably transfected with a hypox-
ia responsive luciferase plasmid [16], were used for monitoring HIF-1
activity in reporter gene studies. Cells were grown to 40% conﬂuence
on 24-well plates with 0.5 ml medium per well. Experimental periods
were 24 h. Thereafter, cells were washed with PBS and lysed with pas-
sive lysis buﬀer (Promega, Mannheim, Germany). Luminescence was
measured with a Micro Lumate (LB 96P; Berthold Technologies,
Bad Wildbad, Germany).
2.6. Enzyme-linked immunoassay (ELISA)
Parental HepG2, IjBa-HepG2 or IjBaM-HepG2 cells were seeded
in 24-well plates and grown to 90–95% conﬂuence. For study, cultures
were washed thoroughly with fresh medium and incubated under hyp-
oxic conditions for 24 h. Epo concentrations were measured in cell cul-
ture supernatants by commercial ELISA (Medac, Wedel, Germany).2.7. Reverse transcription and polymerase chain reaction (RT-PCR)
Total RNA was isolated according to Chomczynski and Sacchi [20]
or with the ABI Prism 6100 NucleicAcid PrepStation (Applied Bio-
systems, Darmstadt, Germany). One microgram of total RNA was re-
verse transcribed into cDNA using oligo (dT) primers. Target cDNAs
were quantiﬁed by real-time RT-PCR on an ABI 7000 Sequence detec-
tion system (Applied Biosystems) by means of either a commercial
SYBR green PCR kit (for the detection of L28; Eurogentec, Seraing,
Belgium) or Assays-on-Demand (for the detection of Epo; Applied
Biosystems, part number 4331182). Relative expression levels were cal-
culated using the DDCT-method (normalized to L28 and related to the
normoxic control). L28 primer sequences were: L28-for-48: 5 0-ATG
GTC GTG CGG AAC TGC T-3 0 and L28-rev-149: 5 0-TTG TAG
CGG AAG GAA TTG CG-3 0.
2.8. Statistics
Results are shown as means + standard deviations (SD). Student’s t-
test was applied to compare mean values in cultures without and with
Bt2-cAMP. A signiﬁcant diﬀerence was assumed at P 6 0.05.3. Results
IL-1 (300 pg/ml) reduced the amount of immunoreactive
Epo produced in hypoxically incubated (3% O2) HepG2
cultures (Fig. 1A). The addition of Bt2-cAMP (50 lM) partly
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Real time RT-PCR measurements showed that IL-1 treated
cells expressed only 50% of the amount of Epo mRNA in hyp-
oxic control cells after 8 h of incubation (Fig. 1B). Bt2-cAMP
moderately increased Epo mRNA levels in IL-1 treated cells.
Measurements by MTT assay proved that neither IL-1 nor
Bt2-cAMP were cytotoxic when added to the cultures for 24 h.
Immunoblotting of nuclear extracts of HepG2 cells revealed
that IL-1 stimulated the translocation of NF-jB p50 and p65
subunits (Fig. 2A). Bt2-cAMP slightly weakened the induction
of NF-jB by IL-1. Clearly, IL-1 increased NF-jB DNA-bind-Fig. 2. (A) Western blot of p50 and p65 NF-jB subunits in nuclear extracts
hypoxic HepG2 cells treated with 300 pg/ml IL-1 (HOX + IL-1), 10 lM Bt2-
for 1 h were subjected to SDS–PAGE. Abbreviation. unsp., unspeciﬁc signal.
binding in nuclear extracts from HepG2 cells maintained at 20% O2 (NOX) or
ml IL-1 (HOX + IL-1), 10 lM Bt2-cAMP (HOX + cAMP) or the combinatio
p65, DNA-binding of p65/p65 homodimers; p65/p50, DNA-binding of p65/p
unspeciﬁc DNA-binding; free probe, unbound oligonucleotides. (C) Repor
reporter plasmid and cultivated at 20% O2 (NOX) or 7% O2 (HOX) for 2
(NOX + IL-1, HOX + IL-1), 50 lM Bt2-cAMP (NOX + Bt2-cAMP, HOX +
1 + Bt2-cAMP, HOX + IL-1 + Bt2-cAMP) for 22 h. Luciferase activity in cul
the respective culture without Bt2-cAMP, mean + SD, n = 4, Student’s t-test
NF-jB-responsive element; SV40, minimal promoter of the Simian virus 40;
signal.ing (homodimers and heterodimers; Fig. 2B). Bt2-cAMP alone
did not alter the pattern of NF-jB DNA-binding. However,
Bt2-cAMP strongly blocked IL-1 induced NF-jB DNA-bind-
ing (Fig. 2B).
To further prove the importance of NF-jB in modulating
the eﬀects of Bt2-cAMP, NF-jB dependent reporter-gene as-
says were performed. IL-1 induced luciferase activity in nor-
moxia as well as in hypoxia. Bt2-cAMP did not alter NF-jB
dependent luciferase activity in the absence of IL-1, whereas
Bt2-cAMP greatly blocked the IL-1 eﬀect (Fig. 2C). However,
hypoxia alone was suﬃcient to slightly induce NF-jB depen-(25 lg) from normoxic (20% O2: NOX), hypoxic (3% O2: HOX) and
cAMP (HOX + cAMP) or with a combination of IL-1 and Bt2-cAMP
Equal loading was veriﬁed by detection of b-actin. (B) NF-jB DNA-
3% O2 (HOX) for 1 h. Hypoxic cultures were also treated with 300 pg/
n of IL-1 and Bt2-cAMP (HOX + IL-1 + cAMP). Abbreviations. p65/
50 heterodimers; p50/p50, DNA-binding p50/p50 homodimers; unsp.,
ter gene assay on HepG2 cells transiently transfected with a NF-jB
4 h. After a medium renewal cells were treated with 100 pg/ml IL-1
Bt2-cAMP) or the combination of IL-1 and Bt2-cAMP (NOX + IL-
tures exposed to normoxia (NOX) was set to 1. *P 6 0.05 compared to
. (D) Schematic drawing of the used NF-jB reporter construct. NRE,
luciferase, luciferase gene of Photinus pyralis; AAA, SV40 late poly(A)
3156 C. Batmunkh et al. / FEBS Letters 580 (2006) 3153–3160dent luciferase activity. A schematic drawing of the used repor-
ter plasmid is seen in Fig. 2D.
Epo production was compared in genetically engineered
HepG2 cells that either overexpressed IjBa (IjBa-HepG2)
or expressed a dominant/negative isoform of IjBa with two
Ser/Ala point-mutations (Ser 32 and Ser 36; IjBaM-HepG2).
The IjBa-HepG2 cells should behave like the parental HepG2
cell line, whereas the IkBaM-HepG2 line should be less able to
activate NF-jB upon IL-1 stimulation. IL-1 treatment reduced
the rate of Epo production in IjBa-HepG2 but not in IjBaM-
HepG2 cultures (Fig. 3A). Bt2-cAMP partly prevented the
reduction of Epo production in IL-1 treated IjBa-HepG2
cells. To further characterize the genetically modiﬁed HepG2
lines, phosphorylated IjBa proteins were quantiﬁed. Immuno-
blotting of whole cell extracts in response to IL-1 revealed
strong phosphorylation of IjBa proteins in parental HepG2
and in IjBa-HepG2 cells, while IjBaM-HepG2 cells showed
only weak phosphorylation of IjBa proteins (Fig. 3B). Fur-
thermore, overexpression of the mutated form of IjBa de-
creased NF-jB DNA-binding. This eﬀect was most
prominent for p50/p50 homodimers.Fig. 3. (A) Epo concentrations in cell culture supernatants of IjBa-HepG2 a
50 lM Bt2-cAMP (HOX + cAMP), 300 pg/ml IL-1 (HOX + IL-1) or the c
*P 6 0.05 compared to the respective cultures without Bt2-cAMP, mean + SD
by Western blot analysis. HepG2, IjBa-HepG2 and IjBaM-HepG2 cells
micrograms of whole cell extracts were subjected to SDS–PAGE. Cells were st
veriﬁed by detection of b-actin. (C) EMSA for NF-jB DNA-binding activity
Five micrograms of nuclear extracts from non-stimulated normoxic (20% O2
were used for EMSAs. Binding reactions were run on a 6% non-denaturating
p50/p50, homodimer of p50 subunits; sp. comp, speciﬁc competitor; unsp.
Speciﬁcity of signals was veriﬁed by supershift analysis with anti-p50 and an
p65). Antibodies were added to the binding reactions prior to the labelled oHypoxic incubation of HepG2 cells resulted in a loss of
the GATA-2 DNA-binding seen on normoxic incubation
(Fig. 4A and B). IL-1 restored GATA-2 DNA-binding un-
der hypoxic conditions. Bt2-cAMP administration also in-
creased GATA-2 DNA-binding in hypoxic cells. IL-1 and
Bt2-cAMP did not exert additive eﬀects. Speciﬁcity was dem-
onstrated by adding unlabelled probe to the binding reaction
(Fig. 4C).
HIF-1a was not detectable in nuclear extracts from norm-
oxic cells. IL-1 treatment resulted in moderately increased
HIF-1a levels (Fig. 5A and B). Hypoxia led to a strong accu-
mulation of nuclear HIF-1a, which was further increased by
IL-1 treatment. Bt2-cAMP did not aﬀect HIF-1a protein
amounts under any condition studied. HIF-1 DNA-binding
complexes were not detectable in nuclear extracts from norm-
oxic cells (Fig. 5C and D). Strong HIF-1 DNA-binding was
seen in cells exposed to hypoxia for 4 h. IL-1 increased this ef-
fect. Bt2-cAMP did not alter HIF-1 DNA binding (Fig. 5C and
D). Furthermore, Bt2-cAMP did not alter HIF-1 dependent
luciferase activity in hypoxic or in IL-1 treated cultures
(Fig. 6).nd IjBaM-HepG2 cells incubated at 3% O2 (HOX) and treatment with
ombination of IL-1 and Bt2-cAMP (HOX + IL-1 + cAMP) for 24 h.
, n = 5, Student’s t-test. (B) Detection of phosphorylated IjBa proteins
were exposed to the experimental conditions for 45 min. Twenty-ﬁve
imulated with 300 pg/ml IL-1 or were left untreated. Equal loading was
in HepG2, IjBa-HepG2 and IjBaM-HepG2 cells in response to IL-1.
NOX) cells and normoxic cells stimulated with 300 pg/ml IL-1 for 1 h
PAA gel. Abbreviations. p65/p50, heterodimer of p65 and p50 subunits;
comp, unspeciﬁc competitor; free probe, unbound oligonucleotides.
ti-p65 antibodies (HepG2 + IL-1 + anti-p50 and HepG2 + IL-1 + anti-
ligonucleotides.
Fig. 4. (A) GATA-2 DNA-binding in nuclear extracts (5 lg) from normoxic HepG2 cells (20% O2: NOX), hypoxic cells (3% O2: HOX) and hypoxic
cells treated with 300 pg/ml IL-1 (HOX + IL-1), 10 lM Bt2-cAMP (HOX + cAMP) or with the combination of IL-1 and Bt2-cAMP (HOX + IL-
1 + cAMP) for 4 h. Abbreviations. GATA-2, GATA-2 speciﬁc DNA-binding; unsp., unspeciﬁc DNA-binding; free probe, unbound oligonucleotides.
(B) Relative GATA-2 DNA-binding was determined by densitometric evaluation of the signals, with signal intensities of the normoxic samples being
set to 1. *P 6 0.05 compared to the respective control cultures without Bt2-cAMP, mean + SD, n = 5, Student’s t-test. (C) Speciﬁcity of GATA-2
DNA-binding was veriﬁed by competition experiments with unlabeled speciﬁc and unspeciﬁc oligonucleotides (50-fold excess of unlabelled
oligonucleotides).
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Insuﬃcent Epo production is not only common in end-stage
renal disease but also in chronic infections, autoimmune dis-
eases and malignancies, thereby contributing to the anemia
of chronic disease (ACD) [21,22]. IL-1 and TNF-a have been
shown to reduce Epo mRNA expression and Epo secretion
in the human hepatoma cell lines HepG2 and Hep3B [10–12]
and to inhibit Epo formation in rat kidneys in vivo and
in vitro [11,13]. On the other side, stimulation of Epo produc-
tion has been observed on the addition of cAMP analogues
(concentration range 10–1000 lM) to hypoxic human hepa-
toma cell cultures in absence of cytokines [12,23]. In the pres-
ent study, up to 50 lM Bt2-cAMP was applied, which proved
to be untoxic for HepG2 cultures. Evidence has been also pro-
vided earlier that cAMP can restore Epo secretion in HepG2
cells treated with IL-1 or TNF-a [12]. Along these lines the
present real-time RT-PCR measurements revealed increased
Epo mRNA levels following the addition of Bt2-cAMP to
IL-1 treated HepG2 cells.
The present ﬁndings suggest that NF-jB is the most impor-
tant transcription factor with respect to the antagonistic eﬀect
of cAMP on the IL-1 repressed production of Epo. Oligo-de-
coy and reporter gene studies from our group have shown that
NF-jB inhibits the Epo promoter [9], although there is a re-
port to the opposite [24]. Gene suppression by NF-jB has been
explained by competition between NF-jB and other transcrip-tion factors for the co-factors p300/CBP [25,26]. The transcrip-
tional co-activators p300/CBP are critically involved in
hypoxia-induced Epo expression [4]. The present studies
showed that IL-1 activated NF-jB DNA-binding. This activa-
tion was prevented, when the cells were treated with Bt2-
cAMP. The role of NF-jB during hypoxia is subject of contro-
versial discussions. It has been reported that NF-jB is acti-
vated by hypoxia in Jurkat T cells, HT29 and HepG2 cells
[27,28] although there is a report on the opposite [29]. Rupec
and Baeuerle [29] demonstrated that NF-jB is strongly acti-
vated upon reoxygenation and that within minutes. This might
be a critical point regarding the outcome of the experiment.
Yao and O’Dywer [28], who reported the activation of NF-
jB by hypoxia, allowed their HepG2 cell cultures to reoxygen-
ate after 24 h of hypoxia and thus it is unclear if NF-jB was
activated by hypoxia or reoxygenation. In our hands and using
HepG2 cells as a model, we only see slight diﬀerences between
normoxic and hypoxic nuclear NF-jB amounts and activity
(Fig. 2A and B). We cannot exclude that this slight induction
is evoked by reoxygenation, even when attention was payed on
harvesting cells quickly on ice and we therefore favor the
hypothesis that NF-jB is not greatly inﬂuenced by hypoxia
alone. In the context of Epo expression one has to take into
account, that the Epo gene is not regulated by one transcrip-
tion factor solely. Instead there are numerous potential bind-
ing sites for diﬀerent transcription factors in the promoter
and the 3 0 enhancer region of the Epo gene. Epo expression
Fig. 5. (A and B) Western blot analysis of HIF-1a protein nuclear extract (25 lg) from HepG2 cells maintained at 20% O2 (NOX) or 3% O2 without
drugs (HOX) or with 300 pg/ml IL-1 (HOX + IL-1), 10 lM Bt2-cAMP (HOX + cAMP) or the combination of IL-1 and Bt2-cAMP (HOX + IL-
1 + cAMP) for 4 h. Equal loading was veriﬁed by detection of Sp1 protein. Relative HIF-1a amounts were determined by densitometry (HIF-1a-
speciﬁc signal/Sp1-speciﬁc signal; hypoxia alone was set to 1). *P 6 0.05 compared to the respective control cultures without Bt2-cAMP, mean + SD,
n = 3, Student’s t-test. (C and D) HIF-1 DNA-binding determined by EMSA in nuclear extracts from HepG2 cells maintained at 20% O2 (NOX) or
3% O2 (HOX) for 4 h. Hypoxic cells were also treated with 300 pg/ml IL-1 (HOX + IL-1), 10 lM Bt2-cAMP (HOX + cAMP) or the combination of
IL-1 and Bt2-cAMP (HOX + IL-1 + cAMP). Speciﬁcity was veriﬁed by supershift analysis (HOX + IL-1 + anti HIF-1a) with an anti HIF-1a
antibody. Abbreviations. unsp., unspeciﬁc DNA-binding; const., constitutive DNA-binding; HIF, HIF-1-speciﬁc DNA-binding; free probe, unbound
oligonucleotides. The bars represent the densitometrical evaluation of HIF-1 speciﬁc signals related to corresponding constitutive signals. The
hypoxic control was set to 1. *P 6 0.05 compared to the respective control cultures without Bt2-cAMP, mean + SD, n = 3, Student’s t-test.
3158 C. Batmunkh et al. / FEBS Letters 580 (2006) 3153–3160is the result of an interplay of many diﬀerent transcription fac-
tors of partly opposite functions. The balance of these tran-
scription factors determine the extent of Epo expression.
Hypoxia, which is the physiological stimulus for increased
Epo production, strongly induces HIF-1, whereas the induc-
tion of NF-jB by moderate hypoxia is, if at all, only very slight
(Fig. 2A and B). In contrast, IL-1 induces NF-jB strongly but
HIF-1 is only moderately activated [9,18]. That means, during
hypoxia there is an overweight of HIF-1 activity and the per-
haps existing slight activity of NF-jB is overrun. The situation
changes when IL-1 induces NF-jB. In this situation there ishigh NF-jB activity and as a result the inhibitory action be-
comes prominent.
To further test for an involvement of NF-jB in the inhibi-
tory action of IL-1 on the Epo gene HepG2 cells stably trans-
fected with a dominant-negative form of the inhibitory protein
IjBa were used. In contrast to its eﬀect in wild-type HepG2
cells or in cells expressing the normal form of IjBa, cAMP
did not antagonize that eﬀect of IL-1 on Epo production in
cells expressing the mutated IjBa. The transcriptional activity
of NF-jB is partly dependent on phosphorylation of NF-jB
p65 [30]. It is thought that the transcriptional co-activator
Fig. 6. (A) Hypoxia dependent reporter gene assay with HRG-1 cells
cultivated at 3% O2 (HOX) without or with 300 pg/ml IL-1
(HOX + IL-1), 10 lM Bt2-cAMP (HOX + cAMP) or with the combi-
nation of IL-1 and Bt2-cAMP (HOX + IL-1 + cAMP) for 22 h.
Luciferase activity in cultures exposed to hypoxia (HOX) was set to
1. *P 6 0.05 compared to the respective control cultures without Bt2-
cAMP, mean + SD, n = 6, Student’s t-test. (B) Scheme of the hypoxia
dependent luciferase reporter construct. TfHRE: Hypoxia responsive
element of the transferrin gene, containing two HIF-1 binding sites,
SV40: minimal promoter of the Simian virus 40, luciferase: luciferase
gene from Photinus pyralis, AAA: SV40 late poly(A) signal.
C. Batmunkh et al. / FEBS Letters 580 (2006) 3153–3160 3159p300/CBP associates with NF-jB p65 in response to PKA
mediated phosphorylation [31]. In harmony with the present
ﬁndings in HepG2 cells, earlier studies have shown that the
activation of NF-jB by IL-1 is also suppressed by cAMP ele-
vation in human pancreatic cancer cells PaCa-2 [32].
GATA-2 blocks the Epo promoter [1,2]. The present study
showed that GATA-2 DNA-binding was reduced under hyp-
oxic condition in HepG2 cells. IL-1 and TNF-a activate
GATA-2 [9,33]. Importantly, the impaired production of
Epo due to the action of IL-1 or TNF-a is rescued by the
GATA-speciﬁc inhibitors K-7174 and K-11706 in vitro and
in vivo [33,34]. Based on the present observation, however,
GATA-2 does not appear to be involved in the eﬀect of cAMP
on IL-1 suppressed Epo production.
HIF-1 is the primary transcription factor in the hypoxic
induction of Epo expression. cAMP response element-binding
protein (CREB) binding protein 1 (CBP-1) has been demon-
strated to bind to the HIF-1 DNA recognition site in HeLa
cells [23,35]. However, in the present study HIF-1 protein lev-
els and HIF-1 DNA-binding were not aﬀected by Bt2-cAMP in
hypoxic and IL-1 treated HepG2 cells. Thus, in this model Bt2-
cAMP was unlikely to stimulate Epo production through the
HIF-1 DNA recognition site.
Reportedly, cAMP stimulates Epo synthesis in human renal
carcinoma and hepatoma cell lines [14,15,36], although drugs
activating the adenylate cyclase/cAMP/PKA pathway fail to
produce a major Epo mRNA increase in rat kidneys during
short term (2 h) perfusion experiments [37]. In a study on hu-
man volunteers the b2-adrenergic receptor agonist fenoterol,
which leads to an endogenous cAMP increase, proved to stim-ulate Epo production in vivo [38]. It remains to be investigated
whether a beneﬁcial value can be assigned to adenylate cyclase
activating drugs in patients suﬀering from impaired Epo syn-
thesis due to high levels of proinﬂammatory cytokines.
Taken together, our results suggest that the elevation of
intracellular cAMP inhibited NF-jB activity thereby partially
restoring cytokine-repressed Epo production. A better under-
standing of the molecular mechanism of the counteraction be-
tween cAMP and IL-1 inhibited Epo production will be
important to design new therapeutic options to treat patients
with ACD.
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